Choosing the Right P2Y12 Inhibitor After PCI – JAMA Cardiology
JAMA Cardiology shared a post on LinkedIn about a recent article by Giuseppe Biondi-Zoccai et al., adding:
“Editorial: A network meta-analysis of randomized clinical trials comparing clopidogrel, prasugrel, and ticagrelor in patients with Acute Coronary Syndrome (ACS) undergoing percutaneous coronary intervention (PCI) indicates that prasugrel offers the most favorable efficacy-safety profile for reducing major adverse cardiovascular events, myocardial infarction, and stent thrombosis.
Clinicians are advised that selection of a P2Y12 inhibitor should be individualized to account for patient comorbidities, bleeding risk, and concurrent therapies, with clopidogrel and ticagrelor remaining appropriate alternatives for specific scenarios.”
Title: Prasugrel – The Default P2Y12 Inhibitor After PCI for ACS?
Authors: Giuseppe Biondi-Zoccai, Salvatore Giordano, Nicola Corcione
Stay updated with Hemostasis Today.
-
Oct 6, 2026, 08:39Emily Bury: Putting Patients at the Centre of VTE Care
-
Oct 6, 2026, 07:44Carolina Moreira Ponce: Thrombosis Month – Why Prevention Starts With Risk Assessment
-
Oct 6, 2026, 07:03Laila Ahmed: Stroke Imaging – A Practical Radiology Approach
-
Oct 6, 2026, 05:52David Esposito: Can Standard Ultrasound Detect May Thurner Syndrome?
-
Oct 6, 2026, 04:33Hessam Kakavand: Rethinking Thrombotic Risk in Modern Cancer Therapy
-
Oct 6, 2026, 04:07Moussa Zein Aldine: Acute Coronary Syndrome Every Minute Matters
-
Oct 6, 2026, 03:13Patrick Taylor: Glow Stack Trend What the Evidence Really Shows
-
Oct 6, 2026, 02:59Preventing Hospital Associated Venous Thromboembolism – Thrombosis Canada
-
Oct 6, 2026, 02:42Treatment of Iron Deficiency With and Without Anemia – American Society of Hematology